Unilever signals pursuit of GSK consumer arm; shares fall




  • In US
  • 2022-01-17 07:28:52Z
  • By Reuters

By Pushkala Aripaka, Keith Weir and Pamela Barbaglia

(Reuters) - Unilever signalled on Monday it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" but its shares fell more than 7%, highlighting investors' doubts about its 50-billion-pound ($68.4 billion) offer.

GSK confirmed over the weekend that it had rejected the Dove soap maker's bid for the business, which is home to brands such as Sensodyne toothpaste, Emergen-C vitamin supplement and Panadol painkiller.

GSK, led by boss Emma Walmsley, has hired Goldman Sachs and Citigroup to review Unilever's approach but it will not engage in talks unless Unilever bumps up its offer, sources familiar with the matter said.

GSK's shares jumped 5% in early trading to their highest level since May 2020. GSK said on Saturday Unilever's proposal "fundamentally undervalued" the business, adding that it would stick to its plan of listing the division this year.

"Initial feedback on the deal from investors over the weekend has been almost uniformly negative," Jefferies analysts said in a note.

Unilever, however, defended the bid for the GSK consumer business, in which U.S. drugs company Pfizer owns a 32% stake.

"The acquisition would create scale and a growth platform for the combined portfolio in the U.S., China and India, with further opportunities in other emerging markets," Unilever said, pointing to synergies in the oral care and vitamin supplements business.

GSK and Pfizer would open negotiations with Unilever's boss Alan Jope if the consumer goods giant was ready to improve its bid to more than 60 billion pounds, a source familiar with Pfizer's strategy said.

The source called the business a "legitimate standalone candidate", adding its market value could rise to almost $100 billion once the business was spun out and listed.

"Right now there is more value in a spin-off but if Unilever is ready to go north of 60 billion pounds then a dialogue could start," he said.

Pfizer did not immediately respond to requests for comment on the fate of GSK's consumer arm.

EXECUTION

A Unilever buyout would be one of the largest ever on the London market and one of biggest deals globally since the start of the pandemic.

It would boost Unilever's growth strategy as management has been under pressure to turn around the company's languishing stock price and cope with high costs and slim margins.

"It's a little surprising that they (GSK) haven't ripped Unilever's arm off at £50bn, as it's a decent price, with the only question being as to whether it's the right one," CMC Markets analyst Michael Hewson said in a note.

"It might be for GlaxoSmithKline and Pfizer, however there is a feeling that for Unilever it could well prove to be too high a price," Hewson added.

Barclays analysts said the deal would be "very complex to execute in normal times, let alone in the middle of a global pandemic".

Unilever, which is set to announce an initiative later this month to strengthen its business, said on Monday it was committed to "strict financial discipline" for any acquisitions, adding that such deals would be accompanied by the divestment of lower margin businesses or brands.

GSK has been pursuing a separate listing of the consumer arm following pressure from investors to explore a shake-up of the company and focus on its pharmaceuticals business.

($1 = 0.7312 pounds)

(Reporting by Pushkala Aripaka and Siddharth Cavale in Bengaluru, Keith Weir and Pamela Barbaglia in London and Ludwig Burger in Frankfurt; Editing by Shounak Dasgupta, Emelia Sithole-Matarise and Jane Merriman)

COMMENTS

More Related News

U.S. CDC recommends re-isolation if COVID recurs after taking Pfizer
U.S. CDC recommends re-isolation if COVID recurs after taking Pfizer's pill

Dozens of individuals have reported rebounding COVID symptoms on social media or to the U.S. Food and Drug Administration after taking Paxlovid, but Pfizer suggests the experience is rare. A recent rise in COVID cases has driven up use of therapeutics in the country.

China
China's bet on homegrown mRNA vaccines holds back nation

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19. As early as the spring of 2020 a Chinese pharmaceutical company, Fosun Pharma, reached an agreement to distribute - and eventually manufacture - the mRNA vaccine made by Pfizer and BioNTech. It still has not been cleared in mainland China, despite being authorized for use by separate authorities in Hong Kong and Macao.

Pfizer
Pfizer's COVID vaccine is safe and appears effective for children under 5, company says

Tests by Pfizer-BioNTech show three COVID shots for children under 5 appear to be safe and effective. The dose is one-tenth as much as for adults.

Pfizer says 3 COVID shots protect children under 5
Pfizer says 3 COVID shots protect children under 5
  • World
  • 2022-05-23 10:46:32Z

Three doses of Pfizer's COVID-19 vaccine offer strong protection for children younger than 5, the company announced Monday. Pfizer plans to give the data to U.S. regulators later this week in a step toward letting the littlest kids get the shots. The Food and Drug Administration has begun evaluating data from rival Moderna, which hopes to begin offering two kid-sized shots by summer.

Pfizer/BioNTech say 3 COVID shots generate good response in under-5s
Pfizer/BioNTech say 3 COVID shots generate good response in under-5s

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under the age ...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • Thank you for an additional great post. Exactly where else could anybody get that kind of facts in this kind of a ideal way of writing? I have a presentation next week, and I’m around the appear for this kind of data.

    REPLY

Top News: US